M. Durante

3.1k total citations
23 papers, 601 citations indexed

About

M. Durante is a scholar working on Genetics, Oncology and Epidemiology. According to data from OpenAlex, M. Durante has authored 23 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Oncology and 8 papers in Epidemiology. Recurrent topics in M. Durante's work include Inflammatory Bowel Disease (9 papers), Microscopic Colitis (8 papers) and Celiac Disease Research and Management (6 papers). M. Durante is often cited by papers focused on Inflammatory Bowel Disease (9 papers), Microscopic Colitis (8 papers) and Celiac Disease Research and Management (6 papers). M. Durante collaborates with scholars based in United States, Netherlands and Canada. M. Durante's co-authors include Elina Berliba, Brian G. Feagan, Marc Ferrante, Bal Raj Bhandari, Geert D’Haens, William J. Sandborn, Jay Tuttle, Stuart Friedrich, Toshifumi Hibi∥ and Jochen Schmitz and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

M. Durante

22 papers receiving 591 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Durante United States	10	242	222	184	153	138	23	601
Menelaos Manoloukos Greece	8	187 0.8×	144 0.6×	176 1.0×	50 0.3×	233 1.7×	9	606
Jamileh Hashemi Sweden	16	252 1.0×	120 0.5×	344 1.9×	97 0.6×	71 0.5×	26	575
Jennifer Curtis United States	10	321 1.3×	88 0.4×	408 2.2×	48 0.3×	123 0.9×	15	672
Catherine E. Willoughby Spain	7	221 0.9×	66 0.3×	244 1.3×	189 1.2×	96 0.7×	8	665
Carla M. van Herpen Netherlands	14	195 0.8×	68 0.3×	325 1.8×	55 0.4×	113 0.8×	27	608
Jennifer A. Grabowsky United States	12	389 1.6×	47 0.2×	274 1.5×	73 0.5×	67 0.5×	29	634
Ignacio Garcia‐Ribas Spain	11	207 0.9×	143 0.6×	442 2.4×	44 0.3×	57 0.4×	33	654
Nathalie Dugot‐Senant France	13	375 1.5×	67 0.3×	119 0.6×	78 0.5×	50 0.4×	30	670
Minish Jain United States	14	258 1.1×	51 0.2×	459 2.5×	82 0.5×	275 2.0×	68	828
Valérie Dessirier France	12	157 0.6×	48 0.2×	125 0.7×	51 0.3×	158 1.1×	14	528

Countries citing papers authored by M. Durante

Since Specialization

Citations

This map shows the geographic impact of M. Durante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Durante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Durante more than expected).

Fields of papers citing papers by M. Durante

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Durante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Durante. The network helps show where M. Durante may publish in the future.

Co-authorship network of co-authors of M. Durante

This figure shows the co-authorship network connecting the top 25 collaborators of M. Durante. A scholar is included among the top collaborators of M. Durante based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Durante. M. Durante is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pai, Rish K., James B. Canavan, Jay Tuttle, et al.. (2020). Tu1849 HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS. Gastroenterology. 158(6). S–1187. 5 indexed citations

Sandborn, William J., Marc Ferrante, Bal Raj Bhandari, et al.. (2020). Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 20(1). 105–115.e14. 48 indexed citations

Sandborn, William J., Marc Ferrante, Bal Raj Bhandari, et al.. (2019). Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 158(3). 537–549.e10. 179 indexed citations

Jairath, Vipul, William J. Sandborn, Yan Dong, et al.. (2019). 709 Optimizing the Definition of Clinical Response Using the Modified Mayo Score: An Analysis of a Phase 2 Study With Mirikizumab in Patients With Ulcerative Colitis. The American Journal of Gastroenterology. 114(1). S417–S417. 1 indexed citations

Durante, M., et al.. (2019). The immediate effects of knee flexion range of motion following manual therapy or self-stretching/active range of motion following a total knee arthroplasty: a case report. Journal of Physical Therapy Science. 31(12). 1002–1005. 2 indexed citations

D’Haens, Geert, William J. Sandborn, Marc Ferrante, et al.. (2019). 1004 – Maintenence Treatment with Mirikizumab, a P19-Directed Il-23 Antibody: 52-Week Results in Patients with Moderately-Toseverely Active Ulcerative Colitis. Gastroenterology. 156(6). S–216. 1 indexed citations

Sandborn, William J., Marc Ferrante, Raj Bhandari, et al.. (2019). P033 EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY. Gastroenterology. 156(3). S23–S23. 1 indexed citations

D’Haens, Geert, William J. Sandborn, Marc Ferrante, et al.. (2019). OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. Journal of Crohn s and Colitis. 13(Supplement_1). S026–S027. 5 indexed citations

Sandborn, William J., Marc Ferrante, Bal Raj Bhandari, et al.. (2019). Tu1711 – Extended Treatment with Mirikizumab in Patients with Moderately-To-Severely Active Ulcerative Colitis: Results from a Phase 2 Trial. Gastroenterology. 156(6). S–1094. 2 indexed citations

10.

Sandborn, William J., Marc Ferrante, Bal Raj Bhandari, et al.. (2018). 882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study. Gastroenterology. 154(6). S–1360. 18 indexed citations

11.

Scifoni, Emanuele, Olga Sokol, Rebecca Grün, et al.. (2016). Helium and Oxygen beam models in TRiP98: implementation, treatment planning tests and experimental verification. Radiotherapy and Oncology. 118. S96–S96. 2 indexed citations

12.

Bruno, Antonino, Elisabetta Pace, M. Durante, et al.. (2016). PT03.3: The Role of Three Different Lycopene Extracts on Human Lung Adenocarcinoma Cell Line. Clinical Nutrition. 35. S27–S27. 1 indexed citations

13.

Münster, Pamela N., Rahul Aggarwal, David S. Hong, et al.. (2015). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 22(8). 1932–1939. 83 indexed citations

14.

Tolcher, Anthony W., Johanna C. Bendell, Kyriakos P. Papadopoulos, et al.. (2014). A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Annals of Oncology. 26(1). 58–64. 100 indexed citations

15.

Arkenau, Hendrik‐Tobias, Joaquı́n Mateo, Charlotte Lemech, et al.. (2014). A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. Journal of Clinical Oncology. 32(15_suppl). 2514–2514. 22 indexed citations

16.

Johnston, Stephen, Henry Gómez, Salomon M. Stemmer, et al.. (2013). A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Research and Treatment. 137(3). 755–766. 33 indexed citations

17.

Infante, Jeffrey R., Kyriakos P. Papadopoulos, Johanna C. Bendell, et al.. (2013). A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer. 49(9). 2077–2085. 64 indexed citations

18.

Münster, Pamela N., Ruud van der Noll, Jennifer M. Specht, et al.. (2012). PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826). Annals of Oncology. 23. ix153–ix154. 11 indexed citations

19.

Infante, Jeffrey R., Amita Patnaik, Suzanne F. Jones, et al.. (2011). Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results.. Molecular Cancer Therapeutics. 10(11_Supplement). B128–B128. 6 indexed citations

20.

Johnston, S., et al.. (2010). 380 A novel skin assessment tool for inflammatory breast cancer (IBC). European Journal of Cancer Supplements. 8(3). 168–168. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact